Secukinumab, an IL-17A inhibitor, significantly reduces subclinical enthesitis in patients with moderate-to-severe plaque psoriasis, according to a study published in the journal Skin. By targeting inflammation at the attachment points of tendons and ligaments before joint pain begins, this treatment may prevent irreversible structural damage associated with psoriatic arthritis (PsA), researchers from The Second Affiliated Hospital of Henan University of Science and Technology report.
How does subclinical enthesitis precede joint damage?
Enthesitis acts as a silent precursor to psoriatic arthritis. It involves inflammation at the entheses, the specific sites where tendons and ligaments connect to bone. Because these changes often occur without external symptoms, routine clinical examinations frequently miss them. According to research published in Skin, musculoskeletal ultrasound is capable of detecting these hidden inflammatory changes.
The study observed significant thinning at multiple enthesial sites, with the most notable at the right Achilles tendon (P = 2.71×10⁻⁹).
What were the results of the secukinumab trial?
In a retrospective study of 76 patients with moderate-to-severe plaque psoriasis, researchers administered 300 mg of secukinumab over six weeks. The findings, published in May 2026, showed that all skin condition scores—including PASI, DLQI, BSA, and IGA—improved with a statistical significance of P < 0.001. Beyond skin clearance, ultrasound imaging confirmed that the medication effectively reduced inflammatory edema within the entheses.
Why is early screening important for psoriasis patients?
Early intervention is critical because it aims to halt the disease process before permanent structural damage occurs. By identifying subclinical enthesitis through ultrasound screening, clinicians can initiate biologic therapies like secukinumab sooner. According to the study authors, this approach could potentially delay clinical PsA.
If you have a diagnosis of moderate-to-severe plaque psoriasis, ask your rheumatologist or dermatologist if a musculoskeletal ultrasound could help assess your risk for subclinical enthesitis.
Future trends in psoriatic arthritis prevention
The shift toward “ultra-early” detection marks a change in how autoimmune diseases are managed. While traditional methods wait for the patient to report joint pain, future protocols may rely on routine imaging for high-risk patients. This proactive strategy mirrors trends in other inflammatory conditions where treating “pre-disease” states has become a priority to improve long-term patient outcomes.
Frequently Asked Questions
What is subclinical enthesitis?
It is inflammation at the connection point between bone and tendon that does not yet cause visible or painful symptoms but can be detected via ultrasound.
Can secukinumab stop psoriatic arthritis?
The study suggests that secukinumab can resolve subclinical inflammation, which may prevent the progression to irreversible structural damage, effectively delaying the onset of clinical PsA.
How is this condition diagnosed?
Diagnosis in the absence of symptoms is achieved through musculoskeletal ultrasound, which allows clinicians to visualize inflammatory edema.
Are you managing psoriasis and concerned about joint health? Share your experiences in the comments below or subscribe to our newsletter for the latest updates on autoimmune research and treatment breakthroughs.
